Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Peritoneal equilibration test revealed that slow, medium, and fast transport status was found in 11%, 78%, and 11% in the GLU group, while 38%, 50%, and 12% in the ICO group, respectively (p = 0.414).Clinical and laboratory data at baseline and follow-up according to each group.Glucose group N = 10Icodextrin group N = 12BaselineFollow-upChangeBaselineFollow-upChangeAge, years51 ± 1846 ± 18Female sex, %9067Weight, kg 68.0 ± 15.6 69.3 ± 13.3 0.8 (− 3.1/5.3) 65.5 ± 9.2 66.2 ± 10.0 1.6 (-4.1/4.6)ECW/TBW 0.46 ± 0.05 0.46 ± 0.05 0 (− 0.01/0.01) 0.39 ± 0.02# 0.40 ± 0.12# 0 (− 0.01/0.02)Diuresis, ml 300 (37/925) 100 (0/835) − 25 (− 262/185) 550 (75/1325) 300 (0/500)* − 300 (− 575/− 25)SBP, mmHg 144 ± 26 121 ± 26 − 28 (− 41/10) 140 ± 30 146 ± 19# 10 (− 17/17)#DBP, mmHg 87 ± 18 75 ± 16 − 12.5 (− 30.0/− 0.25) 87 ± 19 86 ± 18 − 5.0 (− 17.5/7.5)UF, ml 775 (575/1.100) 925 (800/1.050) 50 (− 25/250) 880 (625/1050) 1,000 (800/1675)* 250 (− 45/550)BNP, ng/ml 4.9 (3.5/16.2) 3.9 (2.1/15.3) 1.2 (− 3.0/4.3) 4.9 (1.2/45.0) 17.7 (5.9/42.5) 4.0 (36.6/33.9)Renal Kt/V 0.68 ± 0.94 0.34 ± 0.59 − 0.05 (− 0.61/0) 0.47 ± 0.51 0.16 ± 0.21 − 0.30 (− 0.35/0)Total Kt/V 2.38 ± 0.81 2.19 ± 0.44 − 0.04 (− 0.74/0.33) 2.29 ± 1.02 1.71 ± 0.56 − 0.60 (− 1.68/0.46)Creatinine, mg/dl 8.5 ± 3.4 9.0 ± 3.6 0.1 (− 1.0/1.9) 12.4 ± 4.6# 10.8 ± 3.2 − 2.0 (− 4.3/1.1)#CRP, mg/dl22 ± 26 5 ± 5− 1.0 (− 55.6/4.7) 8 ± 9 13 ± 16 4.6 (− 0.5/16.0)#Ferritin, ng/ml 297 ± 184 319 ± 282 − 10 (− 82/143) 221 ± 170 211 ± 184 − 29 (− 127/27)Albumin, g/dl 3.6 ± 0.4 4.0 ± 0.5 0.3 (− 1.0/0.6) 3.9 ± 0.4 3.5 ± 0.7 − 0.3 (− 0.6/0.2)#Cholesterol, mg/dl 202 ± 66 198 ± 70 − 8.5 (− 47.5/52.5) 178 ± 43 156 ± 34 − 16.5 (− 32.5/5.0)Triglycerides, mg/dl 188 ± 109 193 ± 106 − 5.5 (− 27.2/33.7) 156 ± 174 115 ± 73 − 11 (− 28. 24)Glucose, g/dl 110.0 ± 26.9 100.5 ± 27.5 − 9.0 (− 20.8/− 3.2) 100.2 ± 55.6 102.7 ± 37.0 0 (− 18/30)Glycated hemoglobin, % 5.6 ± 0.6 5.2 ± 0.7 − 0.2 (− 0.3/0.2) 5.7 ± 1.2 5.9 ± 1.4* − 0.3 (1.4/0.6)Hemoglobin, g/dl 11.2 ± 1.9 11.2 ± 1.9 − 0.2 (− 0.5/1.0) 11.3 ± 2.3 10.9 ± 1.4 0 (− 2.3./0.6)Hematocrit, % 34.3 ± 5.8 33.5 ± 5.8 − 1.2 (− 2.4/2.5) 34.9 ± 7.3 32.9 ± 4.4 − 2.2 (− 6.3/1.1)iCa, mg/dl 4.79 ± 0.19 4.84 ± 0.23 0.07 (− 0.20/0.07) 4.78 ± 0.42 4.79 ± 0.39 0.05 (− 0.21/0.18)tCa, mg/dl 9.8 ± 0.7 10.0 ± 1.0 0.48 (− 0.52/1.03) 8.9 ± 0.6# 8.7 ± 0.7# 0.3 ( − 0.3/0.9)25(OH)Vit.D, ng/ml 19.8 ± 6.4 23.1 ± 8.9 2.6 (− 4.0/8.9) 19.7 ± 6.2 26.2 ± 10.7* 4.9 (0.05/14.2)PTH, pg/ml 293 (176/475) 230 (129/697) − 38 (− 246/67) 392 (245/1032) 327 (228/559) 25 (− 49/234)FGF- 23, pg/ml 343 (104/3,834) 189 (45/4,631) 0 (− 68/153) 1,032 (175/4,761) 1,421 (248/4,738) 146 (0/3,446)AP, UI/ml 76 (67/104) 76 (54/120) 1.5 (− 9.0/11.2) 97 (73/122) 94 (59/113) 4.0 (− 8.8/28.5)ECW/TBW, extracellular water/total body water; SBP, systolic blood pressure; DBP, diastolic blood pressure; UF, ultrafiltration; BNP, brain natriuretic peptide; CRP, C-reactive protein; iCa, ionized calcium; tCa, total calcium corrected by serum albumin; 25(OH)Vit.D. 25 hydroxy-vitamin D; PTH, parathyroid hormone.

Source: Baseline. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A randomized clinical trial to evaluate the effects of icodextrin on left ventricular mass index in peritoneal dialysis

Source: Article title.

Patients were recruited from the Hospital das Clinicas, Universidade de Sao Paulo, and the dialysis unit from the Universidade Federal de Sao Paulo.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

A randomized clinical trial to evaluate the effects of icodextrin on left ventricular mass index in peritoneal dialysis

Randomised controlled trial · Scientific Reports · 2022

Original publication title

A randomized clinical trial to evaluate the effects of icodextrin on left ventricular mass index in peritoneal dialysis

Lilian Cordeiro; Walther Yoshiharu Ishikawa; Maria Claudia C. Andreoli; Maria Eugenia F. Canziani; Luiza Karla R. P. Araujo; Benedito J. Pereira; Hugo Abensur; Rosa M. A. Moysés; Rosilene M. Elias

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Left ventricular hypertrophy is a risk factor for cardiovascular mortality in patients on peritoneal dialysis (PD). Because icodextrin has a greater ultrafiltration power compared with glucose-based solutions for long dwell, it could improve left ventricular mass by reducing fluid overload. This was a randomized clinical trial that included patients on PD recruited from 2 teaching hospitals, in Sao Paulo: Brazil. Patients were allocated to the control glucose group (GLU) or the intervention icodextrin (ICO) group. Clinical and cardiac magnetic resonance image (MRI) parameters were evaluated at baseline and 6 months after randomization.

The primary outcome was the change in left ventricular mass adjusted by surface area (ΔLVMI), measured by cardiac MRI. A total of 22 patients completed the study (GLU, N = 12 and ICO, N = 10). Baseline characteristics such as age, sex, underlying disease, and time on dialysis were similar in both groups. At baseline, 17 patients (77.3%) presented with left ventricular hypertrophy with no difference between groups (p = 0.748). According to the total body water (TBW)/extracellular water (ECW) ratio, 36.8% and 80% of patients from GLU and ICO groups, respectively, were considered hypervolemic (p = 0.044).

During follow-up, ΔLVMI was 3.9 g/m (− 10.7, 2.2) in GLU and 5.2 (− 26.8, 16.8) in ICO group (p = 0.651). ΔLVMI correlated with change in brain natriuretic peptide (r = 0.566, p = 0.044), which remained significant in a multiple regression analysis. The use of the icodextrin-based solution in prevalent patients on PD compared with a glucose-based solution was not able to improve LMV. A larger randomized trial with a longer follow-up period may be needed to show changes in LVM in this patient population.

Trial registration: this study has been registered at ReBEC (Registro Brasileiro de Ensaios Clinicos) under the identification #RBR-2mzhmj2, available at: https://ensaiosclinicos.gov.br/pesquisador.

Authors’ abstract

Left ventricular hypertrophy is a risk factor for cardiovascular mortality in patients on peritoneal dialysis (PD). Because icodextrin has a greater ultrafiltration power compared with glucose-based solutions for long dwell, it could improve left ventricular mass by reducing fluid overload. This was a randomized clinical trial that included patients on PD recruited from 2 teaching hospitals, in Sao Paulo: Brazil. Patients were allocated to the control glucose group (GLU) or the intervention icodextrin (ICO) group. Clinical and cardiac magnetic resonance image (MRI) parameters were evaluated at baseline and 6 months after randomization.

The primary outcome was the change in left ventricular mass adjusted by surface area (ΔLVMI), measured by cardiac MRI. A total of 22 patients completed the study (GLU, N = 12 and ICO, N = 10). Baseline characteristics such as age, sex, underlying disease, and time on dialysis were similar in both groups. At baseline, 17 patients (77.3%) presented with left ventricular hypertrophy with no difference between groups (p = 0.748). According to the total body water (TBW)/extracellular water (ECW) ratio, 36.8% and 80% of patients from GLU and ICO groups, respectively, were considered hypervolemic (p = 0.044).

During follow-up, ΔLVMI was 3.9 g/m (− 10.7, 2.2) in GLU and 5.2 (− 26.8, 16.8) in ICO group (p = 0.651). ΔLVMI correlated with change in brain natriuretic peptide (r = 0.566, p = 0.044), which remained significant in a multiple regression analysis. The use of the icodextrin-based solution in prevalent patients on PD compared with a glucose-based solution was not able to improve LMV. A larger randomized trial with a longer follow-up period may be needed to show changes in LVM in this patient population.

Trial registration: this study has been registered at ReBEC (Registro Brasileiro de Ensaios Clinicos) under the identification #RBR-2mzhmj2, available at: https://ensaiosclinicos.gov.br/pesquisador.

Publication and source details

Original title: A randomized clinical trial to evaluate the effects of icodextrin on left ventricular mass index in peritoneal dialysis

Lilian Cordeiro; Walther Yoshiharu Ishikawa; Maria Claudia C. Andreoli; Maria Eugenia F. Canziani; Luiza Karla R. P. Araujo; Benedito J. Pereira; Hugo Abensur; Rosa M. A. Moysés; Rosilene M. Elias

Scientific Reports · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Fundação de apoio à pesquisa do Estado de Sao Paulo: FAPESP2016/19798-7

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T22:22:06.066370+00:00

DOI: 10.1038/s41598-022-20157-z · PMC9500040